Cover Image
Market Research Report

Breast Cancer Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by Increasing Uptake of Targeted Therapies and Rising Prevalence

Published by GBI Research Product code 353594
Published Content info 215 Pages
Delivery time: 1-2 business days
Price
Back to Top
Breast Cancer Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by Increasing Uptake of Targeted Therapies and Rising Prevalence
Published: May 1, 2018 Content info: 215 Pages
Description

Summary:

Breast cancer is a malignant neoplasm that begins in the breast tissue, which is made up of glands for milk production, called lobules, and the ducts that connect the lobules to the nipples. Most breast cancers are invasive cancers that have grown beyond the ducts or lobules and can metastasize to other parts of the body through the bloodstream and the lymphatic system (ACS, 2013a). The term breast cancer covers a variety of neoplasms that have distinct molecular, histological and genomic properties. As such, the treatment course varies among different patients.

The Asia-Pacific (APAC) breast cancer market was valued at just over $2 billion in 2017, and is expected to grow at a compound annual growth rate (CAGR) of around 11.9% to reach about $4.75 billion in 2024. The major factors that are expected to drive the market include increases in diagnosed prevalence and the annual cost of therapy (ACoT) due to higher uptake of costlier therapies.

HER2-positive breast cancer is an aggressive disease, and historically has had a worse overall survival (OS) than HER2-negative disease, which is considered to be less aggressive. The current marketed drug landscape in breast cancer includes a mix of targeted therapies, chemotherapies, and hormonal agents. Metastatic breast cancer is not considered a curable disease, and in the course of therapy patients can receive up to three lines of endocrine agents and four or more lines of chemotherapy, as well as targeted therapies for earlier lines of therapy - often in no particular sequence. Hormone therapy is the mainstay of treatment for patients with HR-positive disease, but triple-negative breast cancer (TNBC) patients who lack HR expression are normally treated with generic chemotherapies.

The report "Breast Cancer Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by Increasing Uptake of Targeted Therapies and Rising Prevalence" will enable you to -

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the breast cancer market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet neds are highlighted to allow a competitive understanding of gaps in the market.
  • Analyze the breast cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict breast cancer market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the breast cancer deals landscape by analyzing trends in licensing and co-development deals.

Scope:

The breast cancer Asia-Pacific market will be valued at $4.75 billion in 2024, growing from $2.16 billion in 2017 at a compound annual growth rate (CAGR) of 11.9%.

  • How will immune checkpoint inhibitors such as Keytruda and Tecentriq, PARP inhibitors such as Lynparza and talazoparib, and PI3K inhibitors such as taselisib and alpelisib contribute to growth?
  • What effect will the patent expirations of branded therapies have on market value?

The breast cancer pipeline is large and diverse, with a strong presence of mAbs and targeted therapies.

  • What are the common targets and mechanisms of action of pipeline therapies?
  • Will the pipeline address unmet needs such as the lack of targeted therapies available for TNBC patients?
  • What implications will the increased focus on targeted therapies have on the future of breast cancer treatment?

Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.

  • How have the late-stage therapies performed in clinical trials?
  • How would the approval of Keytruda, Tecentriq, Lynparza, talazoparib and ipatasertib to treat TNBC patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?

The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.

  • How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?
  • How could changes in risk factors such as population age, early menstruation, late menopause, obesity, smoking, lack of breast-feeding and alcohol consumption influence the market?

Licensing deals are the most common form of strategic alliance in breast cancer, with total deal values ranging from under $10m to over $1 billion.

  • How do deal frequency and value compare between target families and molecule types?
  • What were the terms and conditions of key licensing deals?

Reasons to buy:

This report will enable you to -

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the breast cancer market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
  • Analyze the breast cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict breast cancer market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the breast cancer deals landscape by analyzing trends in licensing and co-development deals.
Table of Contents
Product Code: GBIHC474MR

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Introduction
  • 2.2. Symptoms
  • 2.3. Etiology
  • 2.4. Pathophysiology
    • 2.4.1. HER2 Testing
    • 2.4.2. Other Biomarkers
  • 2.5. Epidemiology
  • 2.6. Diagnosis and Classification
  • 2.7. Prognosis and Disease Staging
  • 2.8. Treatment Options
    • 2.8.1. Surgery and Radiation Therapy
    • 2.8.2. Chemotherapy
    • 2.8.3. Hormonal Therapies
    • 2.8.4. Targeted Therapies
  • 2.9. Treatment Guidelines

3. Marketed Products

  • 3.1. Overview
    • 3.1.1. Herceptin (trastuzumab) - Roche/Genentech
    • 3.1.2. Perjeta (pertuzumab) - Roche/Genentech
    • 3.1.3. Kadcyla (ado-trastuzumab emtansine) - Roche/Genentech
    • 3.1.4. Tykerb/Tyverb (lapatinib ditosylate monohydrate) - Novartis
    • 3.1.5. Ibrance (palbociclib) - Pfizer
    • 3.1.6. Kisqali (ribociclib) - Novartis
    • 3.1.7. Halaven (eribulin mesylate) - Eisai
    • 3.1.8. Avastin (bevacizumab) - Roche/Genentech
    • 3.1.9. Afinitor (everolimus) - Novartis
    • 3.1.10. Abraxane (Nab-Paclitaxel) - Celgene
    • 3.1.11. Ixempra (ixabepilone) - R-Pharm
    • 3.1.12. Doxil/Caelyx (pegylated liposomal doxorubicin) - Johnson & Johnson
    • 3.1.13. Faslodex (fulvestrant) - AstraZeneca
    • 3.1.14. Tamoxifen
    • 3.1.15. Aromatase Inhibitors (AIs)
  • 3.2. Comparative Efficacy and Safety of Marketed Products

4. Pipeline Analysis

  • 4.1. Overview
  • 4.2. Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
    • 4.2.1. Pipeline by Molecular Target
  • 4.3. Promising Pipeline Molecules
    • 4.3.1. Nerlynx (Neratinib) - Puma Biotechnology
    • 4.3.2. Verzenio (abemaciclib) - Eli Lily
    • 4.3.3. Lynparza (olaparib) - AstraZeneca
    • 4.3.4. Talazoparib - Pfizer/BioMarin
    • 4.3.5. Keytruda (pembrolizumab) - Merck & Co.
    • 4.3.6. Tecentriq (atezolizumab) - Roche
    • 4.3.7. Taselisib - Genentech
    • 4.3.8. Alpelisib - Novartis
    • 4.3.9. Margetuximab - MacroGenics
    • 4.3.10. OBI-822/821(adagloxad simolenin) - OBI Pharma
    • 4.3.11. Utidelone (UTD-1) - Beijing Biostar Technologies
    • 4.3.12. Pyrotinib (HTI1001/SHR1258) - Jiangsu Hengrui Medicine
    • 4.3.13. Ipatasertib (RG-7440/GDC-0068) - Array Biopharma/Genentech
    • 4.3.14. Epidaza (Tucidinostat/ HBI8000/ CS055) - Chipscreen Biosciences
    • 4.3.15. BAT8001 - Bio-Thera Solutions
  • 4.4. Comparative Efficacy and Safety of Pipeline Products
  • 4.5. Product Competitiveness Framework

5. Clinical Trial Analysis

  • 5.1. Failure Rate
    • 5.1.1. Overall Failure Rate
    • 5.1.2. Failure Rate by Phase and Molecule Type
    • 5.1.3. Failure Rate by Phase and Molecule Target
  • 5.2. Clinical Trial Duration
    • 5.2.1. Clinical Trial Duration by Molecule Type
    • 5.2.2. Clinical Trial Duration by Molecular Target
  • 5.3. Clinical Trial Size
    • 5.3.1. Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development
    • 5.3.2. Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development
  • 5.4. Competitive Clinical Trials Metrics Analysis

6. Multi-scenario Forecast

  • 6.1. Overview
  • 6.2. Asia-Pacific Market
  • 6.3. India
    • 6.3.1. Treatment Usage Patterns
    • 6.3.2. Annual Cost of Therapy
    • 6.3.3. Market Size
  • 6.4. China
    • 6.4.1. Treatment Usage Patterns
    • 6.4.2. Annual Cost of Therapy
    • 6.4.3. Market Size
  • 6.5. Australia
    • 6.5.1. Treatment Usage Patterns
    • 6.5.2. Annual Cost of Therapy
    • 6.5.3. Market Size
  • 6.6. South Korea
    • 6.6.1. Treatment Usage Patterns
    • 6.6.2. Annual Cost of Therapy
    • 6.6.3. Market Size
  • 6.7. Japan
    • 6.7.1. Treatment Usage Patterns
    • 6.7.2. Annual Cost of Therapy
    • 6.7.3. Market Size

7. Drivers and Barriers

  • 7.1. Drivers
    • 7.1.1. Increased Uptake of Targeted and Combination Therapies for Breast Cancer
    • 7.1.2. Increasing Aging Population and Incident Cases of Breast Cancer
    • 7.1.3. Prolonged Treatment Duration
    • 7.1.4. Expansion of Branded Therapies into the Early Disease Regimen
    • 7.1.5. Diversified Healthcare Reform and Insurance System to Boost Market Growth
  • 7.2. Barriers
    • 7.2.1. Usage of Surgical Therapies at Early Stage Reduces Drug Treatment Rate
    • 7.2.2. Multiple Drugs to Lose Patent Protection in the Forecast Period
    • 7.2.3. Delayed Presentation of Symptoms, Lack of Access and Awareness to Hamper Proper Treatment
    • 7.2.4. High Level of Competition
    • 7.2.5. Drug Pricing Reforms
    • 7.2.6. Problems with the Reimbursement of Premium-Priced Therapeutics will Limit their Uptake

8. Deals and Strategic Consolidations

  • 8.1. Licensing Deals
    • 8.1.1. Deals by Region and Value
    • 8.1.2. Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
    • 8.1.3. Deal Value by Stage of Development, Molecule Type, and Molecular Target
    • 8.1.4. Key Licensing Deals
  • 8.2. Co-development Deals
    • 8.2.1. Deals by Region and Value
    • 8.2.2. Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
    • 8.2.3. Deal Value by Stage of Development, Molecule Type, and Molecular Target
    • 8.2.4. Key Co-development Deals

9. Appendix

  • 9.1. All Pipeline Drugs by Stage of Development
    • 9.1.1. Discovery
    • 9.1.2. Preclinical
    • 9.1.3. IND/CTA- filed
    • 9.1.4. Phase I
    • 9.1.5. Phase II
    • 9.1.6. Phase III
    • 9.1.7. Pre-registration
  • 9.2. Summary of Multi-scenario Market Forecasts to 2022
    • 9.2.1. Asia-Pacific
    • 9.2.2. India
    • 9.2.3. China
    • 9.2.4. Australia
    • 9.2.5. South Korea
    • 9.2.6. Japan
  • 9.3. Bibliography
  • 9.4. Abbreviations
  • 9.5. Research Methodology
    • 9.5.1. Secondary Research
    • 9.5.2. Marketed Product Profiles
    • 9.5.3. Late-Stage Pipeline Candidates
    • 9.5.4. Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
    • 9.5.5. Product Competitiveness Framework
    • 9.5.6. Pipeline Analysis
    • 9.5.7. Forecasting Model
    • 9.5.8. Deals Data Analysis
  • 9.6. Contact Us
  • 9.7. Disclaimer

List of Tables

  • Table 1: Molecular Subtypes of Breast Cancer
  • Table 2: Definitions of HER2 Status by IHC Staining
  • Table 3: Breast Cancer Therapeutics, Global, Tumor, Nodes and Metastasis Staging, 2010-2013
  • Table 4: Breast Cancer Therapeutics Market, Global, Licensing Deals Valued $100m and Above, 2007-2017
  • Table 5: Breast Cancer Therapeutics Market, Global, Co-development Deals Value, 2007-2017
  • Table 6: Breast Cancer Therapeutics Market, Global, All Pipeline Products, Discovery, 2018
  • Table 7: Breast Cancer Therapeutics Market, Global, All Pipeline Products, Preclinical, 2018
  • Table 8: Breast Cancer Therapeutics Market, Global, All Pipeline Products, IND/CTA- filed, 2018
  • Table 9: Breast Cancer Therapeutics Market, Global, All Pipeline Products, Phase I, 2018
  • Table 10: Breast Cancer Therapeutics Market, Global, All Pipeline Products, Phase II, 2018
  • Table 11: Breast Cancer Therapeutics Market, Global, All Pipeline Products, Phase III, 2018
  • Table 12: Breast Cancer Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2018
  • Table 13: Breast Cancer Therapeutics Market, APAC, Market Forecast, 2017-2024
  • Table 14: Breast Cancer Therapeutics Market, India, Market Forecast, 2017-2024
  • Table 15: Breast Cancer Therapeutics Market, China, Market Forecast, 2017-2024
  • Table 16: Breast Cancer Therapeutics Market, Australia, Market Forecast, 2017-2024
  • Table 17: Breast Cancer Therapeutics Market, South Korea, Market Forecast, 2017-2024
  • Table 18: Breast Cancer Therapeutics Market, Japan, Market Forecast, 2017-2024

List of Figures

  • Figure 1: Breast Cancer Therapeutics, APAC, Age-Standardized Incidence (per 100,000 population), 2012
  • Figure 2: Breast Cancer Therapeutics, Australia, Age-Specific Incidence Rate per 100,000 Population, 2012, 2013 and 2014
  • Figure 3: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stages I-III
  • Figure 4: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stage IV
  • Figure 5: Breast Cancer Therapeutics Market, Global, Comparative Efficacy and Safety Heatmap for Marketed Products for the Treatment of HER2-Positive Breast Cancer Patients, 2018
  • Figure 6: Breast Cancer Therapeutics Market, Global, Comparative Efficacy and Safety Heatmap for Marketed Products for the Treatment of HER2-Negative Breast Cancer Patients, 2018
  • Figure 7: Breast Cancer Therapeutics Market, Global, Overview of Pipeline Products, 2018
  • Figure 8: Breast Cancer Therapeutics Market, Global, Molecular Target in the Pipeline
  • Figure 9: Breast Cancer Therapeutics Market, Global, Molecular Target in the Pipeline
  • Figure 10: Breast Cancer Therapeutics Market, APAC, Neratinib, Market Forecast ($m), 2020-2024
  • Figure 11: Breast Cancer Therapeutics Market, APAC, Abemaciclib, Market Forecast ($m), 2018-2024
  • Figure 12: Breast Cancer Therapeutics Market, APAC, Olaparib, Market Forecast ($m), 2018-2024
  • Figure 13: Breast Cancer Therapeutics Market, APAC, Talazoparib, Market Forecast ($m), 2020-2024
  • Figure 14: Breast Cancer Therapeutics Market, APAC, Pembrolizumab, Market Forecast ($m), 2020-2024
  • Figure 15: Breast Cancer Therapeutics Market, APAC, Atezolizumab Forecast ($m), 2021-2024
  • Figure 16: Breast Cancer Therapeutics Market, APAC, Taselisib, Market Forecast ($m), 2020-2024
  • Figure 17: Breast Cancer Therapeutics Market, APAC, Alpelisib, Market Forecast ($m), 2021-2024
  • Figure 18: Breast Cancer Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products for HER2-Positive Breast Cancer, 2018
  • Figure 19: Breast Cancer Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products for HER2-Negative Breast Cancer, 2018
  • Figure 20: Breast Cancer Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products for TNBC, 2018
  • Figure 21: Breast Cancer Therapeutics Market, Competitor Matrix for HER2-Positive Breast Cancer Marketed and Pipeline Products, 2018
  • Figure 22: Breast Cancer Therapeutics Market, Competitor Matrix for HER2-Negative Breast Cancer Marketed and Pipeline Products, 2018
  • Figure 23: Breast Cancer Therapeutics Market, Global, Average Clinical Trial Failure Rate (%), 2007-2017
  • Figure 24: Breast Cancer Therapeutics Market, Global, Clinical Trial Failure Rates by Molecule Type (%), 2007-2017
  • Figure 25: Breast Cancer Therapeutics Market, Global, Clinical Trial Failure Rates by Molecular Target (%), 2007-2017
  • Figure 26: Breast Cancer Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2007-2017
  • Figure 27: Breast Cancer Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2007-2017
  • Figure 28: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type (participants), 2007-2017
  • Figure 29: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Product by Molecular target (participants), 2007-2017
  • Figure 30: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Individual Trial by Molecule Type (participants), 2007-2017
  • Figure 31: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Individual Trial by Molecular Target (participants), 2007-2017
  • Figure 32: Breast Cancer Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
  • Figure 33: Breast Cancer Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
  • Figure 34: Breast Cancer Therapeutics Market, APAC, Treatment Patterns ('000), 2017-2024
  • Figure 35: Breast Cancer Therapeutics Market, APAC, Market Size ($bn), 2017-2024
  • Figure 36: Breast Cancer Therapeutics Market, India, Treatment Patterns ('000), 2017-2024
  • Figure 37: Breast Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2017-2024
  • Figure 38: Breast Cancer Therapeutics Market, India, Market Size ($m), 2017-2024
  • Figure 39: Breast Cancer Therapeutics Market, China, Treatment Patterns ('000), 2017-2024
  • Figure 40: Breast Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2017-2024
  • Figure 41: Breast Cancer Therapeutics Market, China, Market Size ($m), 2017-2024
  • Figure 42: Breast Cancer Therapeutics Market, Australia, Treatment Patterns ('000), 2017-2024
  • Figure 43: Breast Cancer Therapeutics Market, Australia, Annual Cost of Therapy ($), 2017-2024
  • Figure 44: Breast Cancer Therapeutics Market, Australia, Market Size ($m), 2017-2024
  • Figure 45: Breast Cancer Therapeutics Market, South Korea, Treatment Patterns ('000), 2017-2024
  • Figure 46: Breast Cancer Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2017-2024
  • Figure 47: Breast Cancer Therapeutics Market, South Korea, Market Size ($m), 2017-2024
  • Figure 48: Breast Cancer Therapeutics Market, Japan, Treatment Patterns ('000), 2017-2024
  • Figure 49: Breast Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2017-2024
  • Figure 50: Breast Cancer Therapeutics Market, Japan, Market Size ($bn), 2017-2024
  • Figure 51: Breast Cancer Therapeutics Market, Global, Licensing Deals by Region and Value, 2007-2017
  • Figure 52: Breast Cancer Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007-2017
  • Figure 53: Breast Cancer Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007-2017
  • Figure 54: Breast Cancer Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2007-2017
  • Figure 55: Breast Cancer Therapeutics, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2007-2017
  • Figure 56: Breast Cancer Therapeutics Market, Global, Co-development Deals by Region, 2007-2017
  • Figure 57: Breast Cancer Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007-2017
  • Figure 58: Breast Cancer Therapeutics Market, Global, Co-development Deals by Stage of Development, 2007-2017
  • Figure 59: Breast Cancer Therapeutics Market, Global, Co-development Deals by Molecule type and Stage of Development, 2007-2017
  • Figure 60: Breast Cancer Therapeutics Market, Global, Co-development Deals by Molecular Target, 2007-2017
Back to Top